ArticleScience advances2022
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors.
Abstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy, safety, and PD-L1-defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Multimodal Artificial Intelligence in Lung Cancer: From Data Integration to Precision Oncology.Cancers · 2026Review
- Automated measurement of CD8+ T-cell distribution at the tumor epithelial-stromal interface is associated with NSCLC immunotherapy benefit and transcriptomic pathways.Journal of pathology informatics · 2026Article
- Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.Signal transduction and targeted therapy · 2026Article
- Deep learning-driven recognition of panoramic tumor microenvironment features in H&E sections and its application.Journal for immunotherapy of cancer · 2026Review
- Real-time multimodal phenotyping reveals distinct tumour cell dynamics and immune escape mechanisms in T cell therapies.Nature biomedical engineering · 2026Article
- A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.Journal of translational medicine · 2026Observational
- Article
- Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Journal of inflammation research · 2026Review
- A deep learning framework to iDentify prOgnostically releVant cancEr Regions (DOVER) within whole slide histopathology images.Cancer letters · 2026Article
- Path2Omics Enhances Transcriptomic and Methylation Prediction Accuracy from Tumor Histopathology.Cancer research · 2025Article
- Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects.RSC medicinal chemistry · 2025Review
- Pathologist-interpretable breast cancer subtyping and stratification from AI-inferred nuclear features.bioRxiv : the preprint server for biology · 2025Article
- Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction.Journal for immunotherapy of cancer · 2025Review
- Spatial features of tumor-infiltrating lymphocytes in primary lesions of lung adenocarcinoma predict lymph node metastasis.Journal of translational medicine · 2025Article
- Automated cell annotation and classification on histopathology for spatial biomarker discovery.Nature communications · 2025Article
- First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.JCO global oncology · 2025Review
- Immuno-Oncology at the Crossroads: Confronting Challenges in the Quest for Effective Cancer Therapies.International journal of molecular sciences · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Xiangxue WangCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-3341-9871
Cristian BarreraCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-7806-9946
Kaustav BeraCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-9831-6000
Vidya Sankar ViswanathanCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Sepideh Azarianpour-EsfahaniCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Can KoyuncuCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-5990-2226
Priya VeluDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-1652-5971
Michael D FeldmanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6661-4940
Michael YangDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0003-2095-3637
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-2334-5218
Kurt A SchalperDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Haider MahdiMagee-Womens Hospital and Magee-Womens Research Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Cheng LuCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.
Vamsidhar VelchetiDepartment of Hematology and Oncology, NYU Langone Health, New York, NY, USA.
Anant MadabhushiCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-5741-0399
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MClinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MPathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0MOral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2MComputerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1MQuantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1MComputerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1MMR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0MPathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9MNovel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, Vamsidhar Velcheti · 2021 to 2026
$2.7MRadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4MHistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0MBLRD VA I01 BX004121NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002548NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01 CA257612NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U24 CA199374NCI NIH HHS U54 CA254566NCRR NIH HHS C06 RR012463NIBIB NIH HHS R43 EB028736
Abstract
Immune checkpoint inhibitors (ICIs) show prominent clinical activity across multiple advanced tumors. However, less than half of patients respond even after molecule-based selection. Thus, improved biomarkers are required. In this study, we use an image analysis to capture morphologic attributes relating to the spatial interaction and architecture of tumor cells and tumor-infiltrating lymphocytes (TILs) from digitized H&E images. We evaluate the association of image features with progression-free (PFS) and overall survival in non-small cell lung cancer (NSCLC) (
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.